Wells Fargo Downgrades Sangamo Therapeutics to Equal-Weight, Announces $1 Price Target
Wells Fargo Downgrades Sangamo Therapeutics to Equal-Weight, Announces $1 Price Target
富國銀行將Sangamo Therapeutics的評級下調至同等權重,宣佈1美元的目標股價
Wells Fargo analyst Jim Birchenough downgrades Sangamo Therapeutics (NASDAQ:SGMO) from Overweight to Equal-Weight and announces $1 price target.
富國銀行分析師吉姆·伯奇諾將Sangamo Therapeutics(納斯達克股票代碼:SGMO)的評級從增持下調至同等權重,並宣佈了1美元的目標股價。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。